This company seems to have been delisted
Reason: Delisted by Nasdaq
Last recorded trade on: February 22, 2023
Source: https://www.globenewswire.com/en/news-release/2022/12/28/2580400/6948/en/Delisting-of-Securities-of-Tuscan-Holdings-Corp-II-Clovis-Oncology-Inc-ZyVersa-Therapeutics-Inc-Otonomy-Inc-and-Forward-Pharma-A-S-from-The-Nasdaq-Stock-Market.html
Reason: Delisted by Nasdaq
Last recorded trade on: February 22, 2023
Source: https://www.globenewswire.com/en/news-release/2022/12/28/2580400/6948/en/Delisting-of-Securities-of-Tuscan-Holdings-Corp-II-Clovis-Oncology-Inc-ZyVersa-Therapeutics-Inc-Otonomy-Inc-and-Forward-Pharma-A-S-from-The-Nasdaq-Stock-Market.html
Clovis Oncology
CLVS
0,06894 €
Share price
0.00%
Change (1 day)
-95.48%
Change (1 year)
Categories
Clovis Oncology (CLVS) - Total debt
Total debt on the balance sheet as of September 2022 : €0.57 Billion
According to Clovis Oncology's latest financial reports the company's total debt is €0.57 Billion. A company’s total debt is the sum of all current and non-current debts.
Clovis Oncology - Total debt on balance sheet (from 2011 to 2022)
Total debt by year
| Year | Total debt | Change |
|---|---|---|
| 2021-12-31 | €0.56 B | 7.17% |
| 2020-12-31 | €0.52 B | -17.55% |
| 2019-12-31 | €0.63 B | 26.59% |
| 2018-12-31 | €0.50 B | 114.11% |
| 2017-12-31 | €0.23 B | -11.94% |
| 2016-12-31 | €0.26 B | 4.41% |
| 2015-12-31 | €0.25 B | 8.29% |
| 2014-12-31 | €0.23 B |
Total debt for similar companies or competitors
| Company | Total debt/th> | differencediff. | Country |
|---|---|---|---|
 BioMarin Pharmaceutical BMRN | €0.51 B | -11.56% | 🇺🇸 USA |
 AstraZeneca AZN | €26.56 B | 4,497.87% | 🇬🇧 UK |
 Pfizer PFE | €52.03 B | 8,905.17% | 🇺🇸 USA |
 Johnson & Johnson JNJ | €44.36 B | 7,577.12% | 🇺🇸 USA |
 AbbVie ABBV | €59.33 B | 10,168.43% | 🇺🇸 USA |
 Eli Lilly LLY | €32.69 B | 5,558.94% | 🇺🇸 USA |